Key Takeaways:
Animal health giant Zoetis Inc. (NYSE: ZTS) is trading at a price-to-earnings ratio of 19, the lowest valuation multiple since the company went public, as controversy surrounding a key drug weighs on investor sentiment. The stock, which historically commanded a premium P/E near 39, has seen its valuation compress after backlash against its osteoarthritis treatment for dogs, Librela.
Analysts are now reassessing the company’s prospects, with Piper Sandler recently reaffirming a “neutral” rating while cutting its price target to $135 from $190. “The key is knowing the difference between minor issues and major ones,” the firm noted, highlighting the brand damage from reports of adverse side effects, including seizures. A class action lawsuit against the company was dismissed late last year.
The controversy directly impacted revenue, with sales for the Librela franchise declining 16 percent in 2025. The entire osteoarthritis pain franchise, which includes Solensia, generated $568 million, accounting for just six percent of Zoetis’ total revenue for the year. Despite this, the company’s total sales still grew two percent in 2025, and it recently reported quarterly revenue of $2.39 billion, beating consensus estimates.
The core debate for investors is whether the current valuation represents a temporary dip or a new normal. With the stock opening Friday at $116.92, just above its 12-month low of $113.29, the current price reflects significant concern. However, management points to a strong pipeline of 12 potential drugs, each with peak sales estimates of over $100 million, and has guided for full-year 2026 EPS between $7.00 and $7.10.
Wall Street remains divided on the stock’s future. While Piper Sandler and Weiss Ratings have taken a more cautious or negative stance, Bank of America maintained a "neutral" rating and raised its price target to $140. The consensus rating remains a "Hold" with an average price target of $152.25, implying potential upside but also acknowledging the risks.
The current P/E of 19 puts Zoetis far below its decade-long average, a level that Wall Street analysts believe justifies a new look, given an expected earnings growth rate of 9.3 percent annually over the next five years. The company's ability to manage the Librela fallout and deliver on its pipeline will be critical.
The stock’s performance in the coming months will test whether this is a generational buying opportunity or a value trap. Investors will be closely watching the sales recovery of the osteoarthritis franchise and updates on the drug pipeline during the company’s next earnings call.
This article is for informational purposes only and does not constitute investment advice.
